Ocular Therapeutix (OCUL) announced that the first patient has been enrolled in the SOL-X long-term extension trial for Axpali for the treatment of wet age-related macular degeneration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix reports additional Axpaxli trial data
- Ocular Therapeutix price target raised to $27 from $24 at BofA
- OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
- Ocular Therapeutix price target raised to $28 from $21 at Clear Street
- Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix